CSL stock faces leadership test as profit outlook holds
Published on 11/03/2026 at 15:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLeadership transition and profit outlook
- Deborah Waterhouse is scheduled to become CSL's chief executive and managing director on February 1, 2027.
- Fiscal 2027 underlying net profit after tax growth remains the central execution target.
- The next leadership handover will test CSL's ability to restore consistent growth across its businesses.
CSL stock traded at 122.78 euros on Lang & Schwarz at 3:31 p.m. CET on Tuesday, November 3, 2026. That was 2.32 percent below the 125.69 euros cited in the latest relevant report published on Friday, October 30, a separate comparison from the daily Xetra close.
The company remains focused on a planned leadership handover and a fiscal 2027 recovery target. CSL's 2026 annual general meeting was held on October 27, according to CSL investor relations.
Waterhouse prepares for February
Deborah Waterhouse is scheduled to become chief executive and managing director on February 1, 2027. Interim chief executive Gordon Naylor is expected to oversee the transition before returning to CSL's board as a non-executive director.
The handover gives investors a defined timetable for the next phase of CSL's recovery. Management has retained its fiscal 2027 outlook for underlying net profit after tax growth of about 5 percent, while revenue is expected to remain broadly in line with the previous year on a constant-currency basis.
Execution remains the key test
The outlook places greater emphasis on operating efficiency, product mix and commercial execution than on broad revenue expansion. Investors will look for evidence that the plasma, vaccines and specialty medicines businesses can support a more reliable earnings path under the incoming leadership.
Follow the real-time quote of CSL stock for the latest Lang & Schwarz indication.
The S&P/ASX 200 provides the relevant market backdrop for CSL's Australian listing; see the latest market coverage.
More news and analyses on CSL stock.
CSL Limited stock at a glance
- Company: CSL Limited
- ISIN: AU000000CSL8
- Ticker: CSL
- Primary exchange: ASX
- Lang & Schwarz quote: 122.78 euros at 3:31 p.m. CET on November 3, 2026
- Change since October 30 report: 2.32 percent below 125.69 euros
